Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD

Background and objectives The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator-methoxy polyethylene glycol-epoetin beta (C.E.R.A.) and to document the efficacy and long-term safety...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fischbach, Michel (VerfasserIn) , Wühl, Elke (VerfasserIn) , Schaefer, Franz (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 06, 2018
In: Clinical journal of the American Society of Nephrology
Year: 2018, Jahrgang: 13, Heft: 1, Pages: 81-90
ISSN:1555-905X
DOI:10.2215/CJN.03570417
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2215/CJN.03570417
Verlag, lizenzpflichtig, Volltext: https://cjasn.asnjournals.org/content/13/1/81
Volltext
Verfasserangaben:Michel Fischbach, Elke Wühl, Sylvie C. Meyer Reigner, Zoe Morgan, and Franz Schaefer

MARC

LEADER 00000caa a2200000 c 4500
001 1698277601
003 DE-627
005 20230427073143.0
007 cr uuu---uuuuu
008 200514s2018 xx |||||o 00| ||eng c
024 7 |a 10.2215/CJN.03570417  |2 doi 
035 |a (DE-627)1698277601 
035 |a (DE-599)KXP1698277601 
035 |a (OCoLC)1341325380 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fischbach, Michel  |e VerfasserIn  |0 (DE-588)1210095351  |0 (DE-627)1698160690  |4 aut 
245 1 0 |a Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD  |c Michel Fischbach, Elke Wühl, Sylvie C. Meyer Reigner, Zoe Morgan, and Franz Schaefer 
264 1 |c January 06, 2018 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.05.2020 
520 |a Background and objectives The study was conducted to identify a conversion factor for switching from previous erythropoiesis-stimulating agents (ESAs) to continuous erythropoietin receptor activator-methoxy polyethylene glycol-epoetin beta (C.E.R.A.) and to document the efficacy and long-term safety of C.E.R.A. in pediatric patients with anemia of CKD undergoing hemodialysis. - Design, setting, participants, & measurements In this open-label, multicenter study, patients aged 6-17 years, with stable chronic anemia of CKD, undergoing hemodialysis received C.E.R.A. every 4 weeks, at a starting dose determined by previous weekly epoetin alfa/beta or darbepoetin dosing. After a 16-week dose-titration and a 4-week evaluation period, patients with stable hemoglobin could enter a 1-year optional safety extension. - Results A total of 64 patients were enrolled. A conversion factor (4 µg every 4 weeks for each weekly dose of 125 IU epoetin alfa/beta or 0.55 µg darbepoetin) was identified that allowed patients to maintain hemoglobin within target levels on switching to C.E.R.A. from another ESA. Using this conversion factor, the adjusted mean change in hemoglobin from baseline to evaluation was −0.09 g/dl (95% confidence interval, −0.45 to 0.26); 81% of patients maintained hemoglobin within 10.0-12.0 g/dl and 75% maintained hemoglobin within 1.0 g/dl of baseline. Results were consistent across age groups (6-11 and 12-17 years) and previous ESA. Thirty-seven patients entered the safety extension period and 17 completed 73 weeks of treatment. Most withdrawals were for kidney transplantation. A total of 70% of patients had hemoglobin within 10.0-12.0 g/dl at last observation, and 62% were within ±1.0 g/dl of baseline. Safety was similar to studies in adult patients, with no new signal detected. - Conclusions Using a defined conversion factor, 4-weekly C.E.R.A. was efficacious in maintaining hemoglobin levels in pediatric patients with stable anemia of CKD undergoing hemodialysis, switching from maintenance treatment with epoetin alfa/beta or darbepoetin. Safety was consistent with the known C.E.R.A. safety profile in adults. 
650 4 |a Adult 
650 4 |a anemia 
650 4 |a C.E.R.A. 
650 4 |a chronic kidney disease 
650 4 |a continuous erythropoietin receptor activator 
650 4 |a epoetin 
650 4 |a Epoetin Alfa 
650 4 |a epoetin beta 
650 4 |a erythropoietin 
650 4 |a Hematinics 
650 4 |a Hemoglobins 
650 4 |a Humans 
650 4 |a kidney transplantation 
650 4 |a Polyethylene Glycols 
650 4 |a renal dialysis 
650 4 |a Renal Insufficiency, Chronic 
700 1 |a Wühl, Elke  |e VerfasserIn  |0 (DE-588)1069939617  |0 (DE-627)823052052  |0 (DE-576)429626134  |4 aut 
700 1 |a Schaefer, Franz  |d 1961-  |e VerfasserIn  |0 (DE-588)1023365383  |0 (DE-627)718365577  |0 (DE-576)366705598  |4 aut 
773 0 8 |i Enthalten in  |a American Society of Nephrology  |t Clinical journal of the American Society of Nephrology  |d Washington, DC : American Society of Nephrology, 2006  |g 13(2018), 1, Seite 81-90  |h Online-Ressource  |w (DE-627)50595091X  |w (DE-600)2216582-4  |w (DE-576)30683281X  |x 1555-905X  |7 nnas 
773 1 8 |g volume:13  |g year:2018  |g number:1  |g pages:81-90  |g extent:10  |a Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD 
787 0 8 |i Errata  |a Fischbach, Michel  |t Correction  |d 2019  |w (DE-627)169828148X 
856 4 0 |u https://doi.org/10.2215/CJN.03570417  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://cjasn.asnjournals.org/content/13/1/81  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200514 
993 |a Article 
994 |a 2018 
998 |g 1023365383  |a Schaefer, Franz  |m 1023365383:Schaefer, Franz  |d 910000  |d 910500  |e 910000PS1023365383  |e 910500PS1023365383  |k 0/910000/  |k 1/910000/910500/  |p 5  |y j 
998 |g 1069939617  |a Wühl, Elke  |m 1069939617:Wühl, Elke  |d 910000  |d 910500  |e 910000PW1069939617  |e 910500PW1069939617  |k 0/910000/  |k 1/910000/910500/  |p 2 
999 |a KXP-PPN1698277601  |e 3666974848 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1698277601"],"doi":["10.2215/CJN.03570417"]},"title":[{"title":"Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD","title_sort":"Efficacy and long-term safety of C.E.R.A. maintenance in pediatric hemodialysis patients with anemia of CKD"}],"recId":"1698277601","note":["Gesehen am 14.05.2020"],"name":{"displayForm":["Michel Fischbach, Elke Wühl, Sylvie C. Meyer Reigner, Zoe Morgan, and Franz Schaefer"]},"person":[{"given":"Michel","role":"aut","display":"Fischbach, Michel","family":"Fischbach","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Wühl, Elke","given":"Elke","roleDisplay":"VerfasserIn","family":"Wühl"},{"given":"Franz","display":"Schaefer, Franz","role":"aut","roleDisplay":"VerfasserIn","family":"Schaefer"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"13","issue":"1","text":"13(2018), 1, Seite 81-90","pages":"81-90","extent":"10","year":"2018"},"origin":[{"dateIssuedKey":"2006","publisherPlace":"Washington, DC","dateIssuedDisp":"2006-","publisher":"American Society of Nephrology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"disp":"American Society of NephrologyClinical journal of the American Society of Nephrology","note":["Gesehen am 04.08.2025"],"id":{"issn":["1555-905X"],"zdb":["2216582-4"],"eki":["50595091X"]},"title":[{"subtitle":"CJASN","title":"Clinical journal of the American Society of Nephrology","title_sort":"Clinical journal of the American Society of Nephrology"}],"corporate":[{"display":"American Society of Nephrology","role":"aut","roleDisplay":"VerfasserIn"}],"titleAlt":[{"title":"CJASN"}],"pubHistory":["1.2006 -"],"recId":"50595091X"}],"language":["eng"],"origin":[{"dateIssuedDisp":"January 06, 2018","dateIssuedKey":"2018"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a FISCHBACHMEFFICACYAN0620